Micron Technology, Inc. vs Novavax Inc — how do they compare? Micron Technology, Inc. trades at $927.43 (market cap $980.90B), while Novavax Inc trades at $7.9 (market cap $1.31B). The key difference: Micron Technology, Inc. is far larger — about 748.8× Novavax Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| MU | NVAX | |
|---|---|---|
Market Cap | $980.90B | $1.31B |
Sector | Technology | Health |
52-Week High | $1.21K | $11.19 |
52-Week Low | $115.79 | $6.22 |
Enterprise Value | $961.25B | $889.30M |
Dividend Yield | 0.06% | — |
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $861.00, down 1.89% amid recent volatility despite strong fundamental performance. The stock shows neutral technical signals with key support at $845 and resistance at $886. Fundamentally, MU demonstrates exceptional profitability with 72.57% gross margins and 55.91% net income margins, supported by three consecutive quarterly earnings beats. Revenue growth accelerated to $37.38 billion in 2025 from $25.1 billion in 2024, with projected 2026 revenue of $90.3 billion indicating robust AI-driven demand.
The outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target representing 79% upside. However, cyclical memory market risks and competitive threats from new entrants like SpaceX's Terrafab facility pose challenges. The stock's current valuation at 19.63 P/E appears reasonable given projected earnings growth, making MU attractive for investors comfortable with semiconductor sector volatility.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Trailing returns across standard periods
Latest headlines on both assets
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →